Evidence map›Paper›PMID 41954387›Full record

ArticleAntimicrobial agents and chemotherapy2026

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for

Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins, Pamela J McShane, Tawanda Gumbo, Shashikant Srivastava

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Sanjay Singh *Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.ORCID 0000-0003-4601-5673
Avneesh ShrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Gunavanthi D BoorgulaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Mary C LongAdvanta Genetics, Tyler, Texas, USA.
Brian RobbinsAdvanta Genetics, Tyler, Texas, USA.
Pamela J McShaneSection of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Tawanda Gumbo *IMPI Group of Companies, Mt. Hampden, Zimbabwe.ORCID 0000-0001-7592-8012
Shashikant SrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.ORCID 0000-0002-8786-8851

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026
$1.7M
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TBR01HD099756 · NICHD · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2019 to 2023
$1.6M
Cystic Fibrosis Foundation Therapeutics KANT23G0National Institute of Allergy and Infectious Diseases 1R01AI179827National Institute of Allergy and Infectious Diseases 1R21AI148096NIAID NIH HHS R01 AI179827NICHD NIH HHS R01 HD099756
6 · The paper itself

Abstract

The guideline-based therapy achieves sputum culture conversion rates in 20%-34% of patients with

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftriaxoneLung DiseasesMycobacterium abscessusMycobacterium Infections, NontuberculousSulbactamDrug Therapy, CombinationHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo CompoundsCeftriaxonedurlobactamSulbactam“double-double” β-lactam-β-lactamase inhibitorsprobability of target attainmenttarget redundancyγ slopes

Identifiers

PMID41954387
PMCPMC13148024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.